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Comprehensive functional characterization of
cancer–testis antigens defines obligate
participation in multiple hallmarks of cancer
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Tumours frequently activate genes whose expression is otherwise biased to the testis,
collectively known as cancer–testis antigens (CTAs). The extent to which CTA expression
represents epiphenomena or confers tumorigenic traits is unknown. In this study, to address
this, we implemented a multidimensional functional genomics approach that incorporates 7
different phenotypic assays in 11 distinct disease settings. We identify 26 CTAs that are
essential for tumor cell viability and/or are pathological drivers of HIF, WNT or TGFb
signalling. In particular, we discover that Foetal and Adult Testis Expressed 1 (FATE1) is a key
survival factor in multiple oncogenic backgrounds. FATE1 prevents the accumulation of the
stress-sensing BH3-only protein, BCL-2-Interacting Killer (BIK), thereby permitting viability in
the presence of toxic stimuli. Furthermore, ZNF165 promotes TGFb signalling by directly
suppressing the expression of negative feedback regulatory pathways. This action is essential
for the survival of triple negative breast cancer cells in vitro and in vivo. Thus, CTAs make
significant direct contributions to tumour biology.
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C
ancer–Testis Antigens (CTAs) were originally discovered
by employing patient-derived cytotoxic T-lymphocytes to
identify the tumour antigens to which they were directed.
Extensive analysis employing genetic, biochemical and differential
gene expression profiling approaches has identified 4250 genes
classified as CTAs1. The testes are necessarily immune privileged
as spermatogenesis generates auto-antigens long after the
development of a competent immune system2. Thus, antigens
derived from anomalously expressed testes proteins can evoke a
cellular and/or humoral immune response and therefore these
proteins are considered targets for immunotherapy3,4. In support
of this, targeting the CTA, NY-ESO-1, using vaccination or
adoptive T-cell transfer has exhibited efficacy in melanoma and
synovial sarcoma patients, respectively5,6.
Given the extensive CTA compendium assembled and with
immune targeting techniques gaining traction, attention is now
turning to the function of CTAs in normal and diseased tissue.
Twenty-four CTAs have been individually deleted in murine
models. The majority of knockouts exhibit defects confined to
gametogenesis. Specifically, CTAs can contribute to chromosome
pairing during meiosis, sperm motility, translational regulation
during sperm maturation, chromatin remodelling and transcrip-
tional regulation7. With respect to tumorigenesis, a handful of
CTAs have been implicated in centrosomal clustering, regulation
of microtubule dynamics, p53 silencing and deflection of
differentiation signalling8–11.
Based on these nascent indications that individual CTAs have
tumorigenic activities, in this study we constructed an investiga-
tional pipeline to define the frequency and nature of CTA
participation in tumorigenic behaviours. From within this cohort,
we present two mechanistic examples that highlight the
dramatically diverse functions CTAs can carry out in tumour
cells. Foetal and Adult Testis Expressed 1 (FATE1) permits
survival in the context of oncogenic stress by recruiting a
previously uncharacterized E3 ligase, RNF183, to degrade the
stress-sensing BH3-only protein, BCL-2-Interacting Killer (BIK).
In comparison, ZNF165 drives the unrestrained activation of
transforming growth factor b (TGFb) signalling by directly
inactivating the expression of negative feedback pathway
regulators, SMURF2, SMAD7 and PMEPA1. These findings
indicate extraordinary flexibility in tumour cell regulatory
networks, rendering them vulnerable to corruption on aberrant
expression of primordial gene-regulatory programmes.
Results
Functional analysis of CTAs. We designed an experimental
platform to allow for broad-scale investigation of the mechanistic
contribution of CTAs to tumour cell autonomous behaviours
(Fig. 1a). One-hundred forty CTAs with documented expression
in solid tumours were selected for this study (Supplementary
Data 1). Given the notorious heterogeneity in expression of CTAs
among tumours, we used quantitative expression profiling to
identify 11 tumour-derived cell lines providing maximal repre-
sentation of CTAs (135 CTAs) (Fig. 1b and Supplementary
Data 2)1. These cell lines were derived from prostate, breast,
ovarian, skin, non-small cell lung cancer (NSCLC) and bone
tumours. Each cell line within this ‘testbed’ exhibited a distinct
pattern of CTA expression; however, most CTAs were present in
42 cell lines and 20% were expressed in all 11 cell lines (Fig. 1b).
To annotate tumorigenic CTAs, we individually depleted each
CTA in each of the 11 cell lines and measured the consequences on
viability, apoptosis and proliferation (Supplementary Fig. 1a–g). In
addition, we measured the consequences of CTA depletion on the
Hypoxia Inducible Factor (HIF), Wnt, TGFb and Nuclear Factor
Kappa-light-chain-enhancer of activated B cells (NF-kB)
signalling pathways in a subset of cell lines using luciferase
reporters (Supplementary Fig. 1b,h,i). These pathways were
chosen because they are classic tumorigenic signalling cascades
that are also essential during development and therefore, we
reasoned were most likely to be affected by CTAs in tumour cells.
Importantly, each luciferase signalling reporter exhibited a broad
dynamic range on ligand-mediated stimulation in at least five
testbed cell lines, providing an opportunity to examine CTA
influence in multiple genetic backgrounds (Supplementary
Fig. 1h,i). Raw data from each screen were normalized to internal
non-targeting controls and a z-score was calculated for all CTAs
in each assay and cell line (Fig. 1c and Supplementary Data 3).
Multiple CTAs are essential for tumour cell viability. Short
interfering RNA (siRNA) pools targeting 17 CTAs that sig-
nificantly affected apoptosis, viability or proliferation (defined as
41.5 s.d. from the mean of all CTAs) were retested using indi-
vidual siRNAs. Fourteen pools contained two or more active
siRNAs, suggesting on-target activity (Fig. 1d–f). Among these
validated CTAs were members of the MAGE (A8 and A2), SSX
(SSX1) and CTAG (CTAG1B) families, which have long been
considered important vaccine targets7. Notably, CTAG1B (also
known as NY-ESO-1), the CTA with clinical efficacy as an
immunotherapeutic target, was required for tumour cell
proliferation. We identified regulators of sperm oxidative
phosphorylation, COX6B2, and sperm migration, CALR3, as
essential for survival12,13. CTAs implicated in regulation of iron
homeostasis, FTHL17, and mitochondrial adhesion in sperm,
SPATA19, were required for proliferation14,15. Validated CTAs
also included proteins with undefined contributions to
spermatogenesis including IGSF11, CSAG1&3, CCDC110,
ZNF165 and FATE1. Taken together, these results indicate that
CTAs with diverse spermatogenic functions can be engaged and
repurposed by the tumorigenic environment to support cell
growth and division.
FATE1 thwarts pro-apoptotic signalling. The CTA that exhib-
ited the most potent viability dependency in multiple genetic
backgrounds was FATE1 (P¼ 0.0011, Kolmogorov–Smirnov test)
(Fig. 2a and Supplementary Data 3). Depletion of FATE1 led to a
430% reduction of viability in melanoma, breast, prostate and
sarcoma settings (Supplementary Fig. 2a). Importantly, three of
the four siRNAs in the original screening pool were sufficient to
recapitulate the activity of the siRNA pool (Fig. 1f). We also
returned FATE1 as essential for viability in a previous genome-
wide loss-of-function screen in H1155 cells, a NSCLC cell line9.
Given this broad penetrance, we further evaluated the tumour cell
dependency on FATE1 by expanding our analysis to additional
cell lines derived from colorectal, ovarian, sarcoma, breast,
cervical and NSCLC cancers. While all cell lines were sensitive
to FATE1 depletion, we identified a subset (HCT116, WHIM12,
U2OS, HeLa, ES-2, PEO1, SUM159, A549, LNCaP), which
exhibited an almost complete loss of viability 120 h post
transfection with siFATE1 (Fig. 2b). In the cleaved caspase-3/7
survival screen, depletion of FATE1 elevated the activity of these
executioner caspases greater than twofold, a phenotype that was
also detectable by immunoblot in a range of tumorigenic settings
and suggests that FATE1 is essential for tumour cell survival
(Fig. 2c and Supplementary Fig. 2b). These observations
corresponded with a potent loss in viability as assessed by
colony formation assays in multiple tumorigenic backgrounds
(Fig. 2d). Importantly, while FATE1 protein was detectable in all
tumour-derived cell lines, it was low or undetectable in
telomerase immortalized, non-tumorigenic fibroblasts and lung
epithelial cells, where siFATE1 did not lead to cleavage of
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Figure 1 | Platform for a multidimensional screen to interrogate CTA function. (a) Workflow for siRNA screen. (b) Presence (red) and absence (white)
calls for all CTAs in indicated cell lines based on quantitative expression analysis. See Supplementary Data 2. (c) Z-scores for each screen were calculated
and plotted for each CTA (left) for each assay and cell line (top, cell lines are hidden). (d–f) SiRNAs were transfected into cell lines, and 96 h post
transfection APO (d), EdU (e) and CTG (f) assays were performed. Bars represent the average mean (n¼ 2)±range. Grey line indicates activity of control
siRNA. Numbers indicate independent siRNA sequences.
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caspase-3 (Fig. 2e). Taken together, these data suggest that
reactivation of FATE1 may be a survival dependency in the
transformed environment irrespective of disease site.
Analysis of FATE1’s secondary structure indicated a largely
disordered protein with the exception of C-terminal coiled-coil
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identity and 55% similarity to mitochondrial fission factor
(Supplementary Fig. 2c–e)16. Consistent with this similarity,
myc-FATE1 localized to the mitochondria with limited presence
in other organelles (Fig. 2f and Supplementary Fig. 2f–h).
Mitochondrial localization was dependent on both the
transmembrane and CC domains, as their deletion resulted in
nuclear and endoplasmic reticular localization, respectively
(Fig. 2f and Supplementary Fig. 2g). Given that mitochondria
are the central hub of apoptotic signalling, we further analysed
the role of key apoptotic regulators in siFATE1-induced death.
Depletion of FATE1 in HCT116 cells induced cleavage of PARP1
and cytochrome c release, a phenotype that was absent in BAX/
BAK null HCT116 cells (Fig. 2g). Overexpression of the anti-
apoptotic Bcl-2 family member, Bcl-xL, also rescued cell death
following siFATE1 (Fig. 2h). Consistent with a general role in
deflecting apoptosis, we found that cells overexpressing FATE1
exhibited attenuated PARP1 cleavage following staurosporine
challenge (Fig. 2i).
To further elaborate the mechanisms of FATE1’s anti-
apoptotic function, we examined FATE1-interacting partners
previously reported by large-scale proteomics studies
(Fig. 3a)17,18. Among the dozen interactors, was the founding
member of the pro-apoptotic BH3-only family, BIK19, which we
found associates with FATE1 in mammalian cells (Fig. 3b). BIK is
reported to promote cell death by mobilizing cytochrome c, which
is released on a parallel signal from NOXA20. BIK can be induced
by genotoxic stress, E2F stimulation, cytokines (IFNg and TGFb),
IgM ligation and oestrogen starvation21. BIK expression is
frequently upregulated in tumours as compared with normal
tissues (Supplementary Fig. 3a); however, BIK protein is low to
undetectable in tumours due to proteasome-mediated turnover,
indicating that tumour cells must adapt mechanisms to prevent
BIK protein accumulation for tumour cell survival21–23. On
depletion of FATE1, we observed a strong stabilization of BIK
protein in multiple tumorigenic settings (Fig. 3c). Significantly,
depletion of BIK rescued siFATE-induced apoptotic signalling
(Fig. 3d), which led us to hypothesize that FATE1 may be
involved in the regulation of BIK stability. While FATE1 does not
have any identifiable E3 ligase domains, we found that it
associated with an uncharacterized E3 ligase, RNF183, in
proteomics analysis and in intact cells (Fig. 3a and
Supplementary Fig. 3b)18. RNF183 is an ER-localized protein
that contains a C3HC4RING domain, which was required for
autoubiquitination activity (Supplementary Fig. 3c–e). In
addition, we found that BIK associated with both FATE1 and
RNF183 in intact cells, suggesting a functional relationship
between these proteins (Fig. 3e). Indeed, RNF183 depletion
increased BIK protein accumulation (Fig. 3f and Supplementary
Fig. 3f). Conversely, overexpression of wild-type RNF183, but not
the C13A/C59A ligase-dead mutant, reduced expression of
exogenous BIK, indicating that RNF183’s E3 activity negatively
regulates BIK protein accumulation (Fig. 3g and Supplementary
Fig. 3e). Given its potent effect on the stabilization of BIK, we
evaluated the consequences of RNF183 depletion on cell viability.
We observed a striking correlation between siFATE1 and
siRNF183 sensitivity in a panel of tumour-derived cell lines
(Fig. 3h,i). These findings indicate that FATE1 and RNF183
collaborate to restrain BIK protein levels, and thus escape from
apoptotic signalling.
To examine the consequences of FATE1 expression in patient
tumours, we examined the Cancer Genome Atlas (TCGA)
colorectal data set, given that depletion of FATE1 was most
potent in the HCT116 colorectal cell line. Here we found that
elevated levels of FATE1 were associated with significantly poorer
survival (hazard ratio (HR)¼ 2.88; P¼ 0.0083; Cox Regression)
(Fig. 3j). In NSCLC, FATE1 expression alone did not portend
poor survival; however, we observed that patients with tumours
expressing elevated FATE1 and RNF183 were at higher risk for
poor survival (HR¼ 2.53; P¼ 0.0007; Cox Regression) as
compared with those patients with one or neither expressed
(Fig. 3k). In a separate NSCLC data set, the majority of tumours
with high FATE1 expression also exhibited elevated RNF183
expression, and again, high expression of both genes predicted
shortened overall survival time (HR¼ 2.80; Po0.0001; Cox
Regression) (Fig. 3l). The frequency of co-expression of RNF183
and FATE1 along with their correlation with poor outcome
reinforces the notion that these proteins are functioning in
human tumours to promote survival.
CTAs are novel regulators of tumorigenic signalling cascades.
We next turned our investigation to the CTAs returned from
screens of regulatory signalling modules. We prioritized siRNAs
from these screens based on the extent and genetic penetrance of
their activity, which returned a large set (410) of CTAs as
putative regulators of each pathway (See Methods and
Supplementary Data 4). We reasoned that this large set could be
due to multiple indirect mechanisms impinging on these signal-
ling modules. Therefore, we asked whether CTAs returned from
these screens were sufficient to activate the pathways for which
they were required. Of the six CTAs tested from the HIF screen,
LDHC, XAGE1B, PAGE4, CTAGE1 and IGF2BP3 were all suf-
ficient to enhance dimethyloxalylglycine-N-(methoxyoxoacetyl)-
glycine methyl ester (DMOG)-mediated activation of the HIF
Figure 2 | FATE1 supports tumour cell viability. (a) Distribution of siFATE1 viability ratios versus all other siCTAs in testbed cell lines with detectable
FATE1 expression. Points represent mean of at least two independent assays. P value calculated by Kolmogorov–Smirnov test. (b) Viability assay in
indicated cell lines 120 h post siRNA transfection. Bars represent mean viability relative to siCTRL (n¼4)±s.d. B, breast; C, cervical; CR, colorectal; L, lung;
S, osteosarcoma; O, ovarian; P, prostate; R, renal. (c) Whole cell lysates (WCLs) from indicated cell lines transfected with siCTRL or siFATE for 48
(HCT116), 72 (SUM159, SUM149, H1155) or 96 h (HeLa, HCC366) were immunoblotted with indicated antibodies. Data representative of a minimum of
two independent assays. (d) Colony formation assays were performed 48 (HCT116) or 72 h after siRNA transfection. Data representative of two
independent assays. (e) WCLs from indicated cell lines were immunoblotted as indicated 96 h after siRNA transfection. Data representative of two
independent assays. (f) HeLa cells transfected with indicated cDNAs for 24 h were fixed, immunostained with indicated antibodies (top) and imaged with
confocal microscopy. WT, wild-type; DTM, transmembrane deletion; DCC, coiled-coiled deletion. Scale bars, 10mm. Data representative of two independent
assays. TOM20 was used to visualize the mitochondria. (g) Top: 48 h after siRNA transfection, WCLs from indicated HCT116 cells (double knockout
(DKO)) were immunoblotted with indicated antibodies. Data representative of two independent assays. Bottom: HCT116 cells were transfected and
exposed to 10mM Q-VD-OPh for 48 h, fixed and immunostained for cytochrome c and TOM20. Cytoplasmic cytochrome c was quantitated manually for
Z200 cells per experiment for each condition. Bars represent mean (n¼ 3)±s.d. Cl, cleaved PARP1; FL, full-length PARP1. (h) WCLs from HCT116 or HeLa
cells stably expressing a control construct (HCT116, empty vector; HeLa, pLPCX-GFP) or myc-Bcl-xL were immunoblotted with indicated antibodies 48
(HCT116) or 72 h (HeLa) post siRNA transfection. (i) H1299 cells stably expressing empty vector or myc-FATE1 were exposed to vehicle or 1 mM
staurosporine for 6 h. WCLs were immunoblotted with indicated antibodies. Data representative of three independent assays.
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response element (HRE) reporter (Fig. 4a). We further examined
IGF2BP3, which exhibited the strongest effect. IGF2BP3 is
expressed in trophoblasts during the first trimester of pregnancy,
and low expression of IGF2BP3 is associated with attenuated
trophoblast invasion and preeclampsia24. Measurement of
canonical HIF targets showed that IGF2BP3 depletion
attenuated the endogenous expression of HIF target genes in
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suggest that reactivation of IGF2BP3 could inappropriately
activate the HIF pathway, promoting invasive and metastatic
behaviour and reducing overall survival. Indeed, in NSCLC,
elevated IGF2BP3 portends poor overall survival (HR¼ 1.84;
P¼ 0.0063; Cox Regression) (Fig. 4c).
Of the 13 CTAs retested from the Wnt screen, SPANXC and
SPANXA2 strongly promoted Wnt-3a-induced TCF4 response
element reporter activity (Fig. 4d). Depletion of multiple SPANX
family members, which was necessary due to high sequence
similarity, inhibited expression of the canonical Wnt target,
AXIN2 (Fig. 4e). In NSCLC, we found that high SPANXA2
expression correlated with poor overall survival (HR¼ 1.64;
P¼ 0.0236; Cox Regression) (Fig. 4f).
We retested six CTAs returned from the NF-kB screen;
however, we were unable to detect a gain-of-function phenotype,
suggesting that these CTAs may support processes that indirectly
impinge on NF-kB signalling.
Of six CTAs tested from the TGFb screen, DDX53, IGSF11
and ZNF165 were sufficient to promote TGFb-induced SMAD
binding element (SBE) reporter activity (Fig. 4g). We analysed
ZNF165 in more detail because its depletion was also selectively
lethal in the TGFb-dependent, triple negative breast cancer
(TNBC) cell line, WHIM12 (Fig. 1c and Supplementary Fig. 4a,b).
Depletion of ZNF165 inhibited activation of the canonical TGFb
target gene, SNAI1, in WHIM12 cells (Fig. 4h). Moreover,
expression of ZNF165 was correlated with poor survival in breast
cancer patients (HR¼ 1.44; P¼ 0.0260; Cox Regression) (Fig. 4i).
ZNF165 attenuates negative feedback of the TGFb pathway.
Based on ZNF165’s correlation with poor outcome in breast
cancer patients, its requirement for viability of WHIM12s and its
augmentation of TGFb pathway activity, we chose to further
investigate how ZNF165 engages TGFb signalling in the setting of
TNBC. As ZNF165 mRNA expression is elevated in multiple
tumour types, we first evaluated ZNF165 protein expression in 10
TNBC, 3 normal and 5 benign-adjacent tissues, including 2
tumour and benign matched pairs (Fig. 5a. and Supplementary
Fig. 4c)25. ZNF165 protein expression was detectable in 9 of the
10 tumour tissues tested, with minimal accumulation in benign or
normal breast-derived samples (Fig. 5a). ZNF165 is an
uncharacterized member of the SCAN-(C2H2)n sub-family of
zinc finger proteins and contains a SCAN heterodimerization
domain and five C2H2 motifs, which are canonical zinc finger
domains that mediate association with DNA (Supplementary
Fig. 4d)26,27. ZNF165 also localizes to the nucleus in tumour cells
and associates with nine proteins with gene-regulatory activity
(Supplementary Fig. 4e,f)18,28. Given these indications of
transcriptional regulatory activity, we performed chromatin
immunoprecipitation followed by next-generation sequencing
(ChIP-Seq) analysis in WHIM12 cells stably expressing ZNF165-
V5 to identify putative target genes. This analysis returned 281
ZNF165 binding sites associated with 447 genes (Supplementary
Data 5). De novo motif enrichment identified three motifs that
comprised B90% of these binding sites (Fig. 5b). Genomic
Regions Enrichment of Annotation Tool (GREAT) analysis
revealed that genes associated with ZNF165 peaks are
significantly enriched in the TGFb signalling pathway (23
genes; q¼ 0.00696, binomial test) (Fig. 5c, Supplementary
Data 5). This gene set contained multiple negative regulators of
TGFb signalling including SMURF2, SMAD7 and PMEPA1,
which we validated as true positives by ChIP–quantitative PCR
(qPCR) (Supplementary Fig. 4g)29–33. As ZNF165 was sufficient
to activate the TGFb reporter, we examined the consequences of
ZNF165 on expression of these negative regulators of TGFb
signalling. First, we verified that SMAD2/3 was phosphorylated in
response to TGFb stimulation in WHIM12 cells (Supplementary
Fig. 4h). As shown in Fig. 5d, TGFb stimulation increased
accumulation of PMEPA1, SMAD7 and SMURF2 mRNA, which
was enhanced on depletion of ZNF165 (Fig. 5d). Conversely, we
found that WHIM12 cells with stable overexpression of ZNF165-
V5 displayed attenuated PMEPA1, SMAD7 and SMURF2 mRNA
expression, suggesting that ZNF165 inhibits expression of these
genes directly (Fig. 5e). An increase in the E3 ligase, SMURF2,
would be predicted to lead to a loss of SMAD2/3 protein, a major
signal transducer of TGFb signalling29,33. Indeed, we found that
depletion of ZNF165 with two independent siRNA pools in
WHIM12 cells led to enhanced SMURF2 accumulation and
attenuation of SMAD2/3 protein (Fig. 5f). We also observed this
phenotype, as well as a decrease in phosphorylation of SMAD2/3,
in a second TNBC- and TGFb-dependent cell line, SUM159
(Supplementary Fig. 4b,i). Conversely, WHIM12-ZNF165-V5
cells exhibited an accumulation of SMAD2/3 protein as compared
with control infected WHIM12s (Fig. 5g). Transient
overexpression of ZNF165 in H1299 cells (a NSCLC-derived
cell line chosen for its high level of transient transfection
efficiency not attainable in the TNBC setting) was also sufficient
to enhance SMAD2/3 protein accumulation (Fig. 5g). To further
evaluate the consequences of ZNF165 on the global TGFb
regulatory network, we performed whole genome expression
profiling in SUM159 and WHIM12 cells depleted of ZNF165 and
stimulated with TGFb (Supplementary Data 6). In both settings,
B25% of all TGFb modulated genes were affected by ZNF165
depletion, representing an enrichment with a probability of
Z3.69 10 11 by random chance according to hypergeometric
distribution analysis (Fig. 5h). In agreement with the ChIP
Figure 3 | FATE1 and the E3 ligase RNF183 impact the stability of the apoptotic effector BIK. (a) Interaction data for FATE1 based on yeast two-hybrid
proteomics analyses. (b) Sixteen hours after transfection in HEK293T cells, lysates (pH 8.0) were incubated with myc antibodies, washed in NDLB and
immunoblotted with indicated antibodies. Data representative of three independent assays. (c) WCLs were collected 48 (HCT116) or 72 h (H1155 and
HeLa) following siRNA transfection and immunoblotted as indicated. þQVD, cells were exposed to 10mM of the pan-caspase inhibitor Q-VD-OPh for the
duration of the experiment. Data representative of at least two independent assays. (d) HCT116 cells were transfected for 24 h with siCTRL or siBIK then
transfected with siCTRL or siFATE for an additional 48 h. WCLs were collected and immunoblotted as indicated. Data representative of three independent
assays. (e) Twenty hours post transfection with BIK-L61G, FATE and HA-RNF183 cDNAs, HEK293T cells were lysed in NDLB, immunoprecipitated and
immunoblotted as indicated. Data representative of two independent assays. (f) WCLs from HCT116 cells transfected with indicated siRNAs for 72 h were
immunoblotted with indicated antibodies. Data representative of two independent assays. (g) WCLs from H1299 cells transfected with indicated cDNAs
for 24 h were immunoblotted as indicated. WT, wild-type. CC/AA, C13A/C59A. Data representative of three independent assays. (h) Cell lines from Fig. 2b
were transfected for 120 h with siFATE (y-axis) or siRNF183 (x-axis) and cell viability was measured via CTG. Dots represent mean of four independent
assays. (i) Viability assays was performed 96 h after siRNA transfection in indicated cell lines. ‘#’ indicates independent siRNA pools. Bars represent mean
(n¼ 3)±s.d. (j) Kaplan–Meier (KM) survival curves from TCGA colorectal adenocarcinoma patients. HR and P value calculated by Cox Regression
Analysis. (k) KM survival curves of patients from GSE42127 as a function of high FATE1- and RNF183-expressing tumours. Venn diagram represents
proportion of patients in each group. HR and P value calculated by Cox Regression Analysis. (l) as in k with patients from GSE8894.
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Figure 4 | CTA expression is sufficient to activate oncogenic signalling cascades. (a) Indicated cDNAs were co-transfected with the HRE luciferase
reporter into HEK293T cells. Following 10 h of stimulation with DMOG, luciferase activity was measured. Bars represent mean (nZ16)±s.e.m. P values
calculated by unpaired Student’s t-test. ****Pr0.0001, ***Pr0.0005, **Pr0.01, *Po0.05. (b) H1299 cells were transfected with indicated siRNAs for
48 h prior to stimulation for 16 h with 1 mM DMOG. Quantitative PCR (qPCR) was used to quantitate relative mRNA expression of indicated genes
normalized to DMOG-stimulated siCTRL. Bars represent mean (n¼ 2)±range. (c) KM survival curves of patients from GSE42127 as a function of IGF2BP3
high- and low-expressing tumours. HR and P value calculated by Cox Regression Analysis. (d) Indicated cDNAs were co-transfected with the Wnt
luciferase reporter into HEK293T cells. Following 10 h of 500 ng ml 1 Wnt-3a stimulation, luciferase activity was measured. Bars represent mean
(nZ8)±s.e.m. P values calculated by unpaired Student’s t-test as in a. (e) Saos-2 cells were transfected with indicated siRNAs for 72 h and exposed to
500 ng ml 1 Wnt-3a for 3 h. QPCR was then performed to quantitate AXIN2 and SPANX mRNA expression. Bars represent mean (n¼ 2)±range. (f) As in
c except the KM plots are a function of SPANXA2 expression levels. (g) Indicated cDNAs were co-transfected with the SBE luciferase reporter in HEK293T
cells. Following 24 h of 100 ng ml 1 TGFb stimulation, luciferase activity was measured. Bars represent mean (nZ4)±s.e.m. P values calculated by
unpaired Student’s t-test as in a. (h) WHIM12 cells were transfected with indicated siRNAs for 48 h and then exposed to 100 ng ml 1 TGFb for 3 h. QPCR
was then performed to quantitate SNAI1 and ZNF165 mRNA expression. Bars represent mean (n¼ 2)±range. (i) As in c, except KM plots are using
patients from the METABRIC data set and are a function of ZNF165 expression.
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analysis, canonical TGFb targets that are negative feedback
regulators (SMURF2 and SMAD7) were activated on ZNF165
depletion (Fig. 5i)29,32,33. ZNF165 was required for the expression
of 30 TGFb-induced genes, many of which mediate neoplastic
processes (GPR124, FGD4, WISP1, DPYSL3, USP2, CRYAB and
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both WHIM12 and SUM159 cells was WISP1, a poorly
characterized oncogene that promotes growth and survival in
colon cancer (Fig. 5i and Supplementary Data 6)36,42,43. We find
that ZNF165 depletion leads to a reduction in WISP1 protein
accumulation (Fig. 5j). Overexpression of ZNF165 is sufficient to
enhance WISP1 mRNA and protein accumulation and stimulate
the activity of luciferase fused to the WISP1 promoter (Fig. 5k
and Supplementary Fig. 4j). Furthermore, WISP1 is essential for
viability in multiple TNBC settings (Fig. 5l and Supplementary
Fig. 4k). Taken together, this analysis indicates that ZNF165
expression directly promotes TGFb pathway activity by
repressing negative feedback and leads to the expression of
target oncogenes essential for TNBC.
ZNF165 is essential for TNBC survival in vitro and in vivo. We
next elaborated on our initial discovery that ZNF165 was essential
for the viability of WHIM12 TNBC cells by assessing this phe-
notype in a larger cohort of tumour and normal, immortalized
breast epithelial cells. Here we found that depletion of ZNF165
selectively reduced viability in a subset of TNBC cell lines (Fig. 6a
and Supplementary Fig. 4l). Depletion of ZNF165 also led to
cleavage of caspase-3 and a decrease in long-term growth as
observed by colony formation assays (Fig. 6b,c). To next examine
the role of ZNF165 during tumorigenesis, we assessed the con-
sequences of ZNF165 depletion in a mouse xenograft model.
WHIM12 cells stably infected with shCTRL or shZNF165 were
injected into immunocompromised mice and tumour growth
monitored for 7 weeks. In comparison to the control shRNA
group, tumours from shZNF165 mice were attenuated in growth
and exhibited reduced Ki-67 staining (Fig. 6d,e). Taken together,
these findings suggest that ZNF165 promotes tumorigenesis by
activating the TGFb pathway, which in TNBC, is essential for
tumour cell survival potentially in part through activation of the
WISP1 oncogene.
Discussion
Intriguing correlative associations between gametogenesis and
tumorigenesis have been noted for over 100 years. For example,
tumour cells can produce trophoblastic hormones at sufficient
levels to be used as a serum marker for tumour detection and
recurrence44. In addition, gene products whose expression is
otherwise restricted to reproductive tissues are frequently re-
expressed in a range of tumour types. However, despite
widespread activation in tumours, a global investigation into
the contribution of these proteins to neoplastic behaviours has
been lacking. Here by integrating findings from a multi-faceted,
comprehensive platform we find that CTAs engage divergent
mechanisms in the tumorigenic regulatory network to promote
cancer.
We uncovered multiple CTAs that are essential for tumour cell
viability. These CTAs have a diversity of known functions within
sperm and therefore likely buttress different aspects of the
tumorigenic platform. In particular, we define FATE1 in
promoting tolerance to cellular stress, which would otherwise
lead to cellular demise. Successful tumorigenesis requires the
circumvention of otherwise fatal fail-safe mechanisms and/or an
adaption to unfavourable physiological conditions. Prototypical
examples include thwarting oncogene-induced pro-apoptotic
signalling, DNA damage stress, toleration of proteotoxic stress
due to aneuploidy and buffering of oxidative stress resulting from
altered mitochondrial function45–47. FATE1 may represent one
mechanism by which tumour cells overcome these barriers by
promoting the degradation of second messengers in this
signalling system. Broadly these findings suggest that the
engagement of lineage-specific gene products may be a
generalizable mechanism to overcome barriers to transformation.
Our studies indicate that CTAs can be sufficient to activate
oncogenic signalling modules. The capacity of ZNF165 to repress
negative feedback of TGFb signalling highlights how the
expression of gametogenic genes in a somatic cell can wreak
havoc on normal homeostatic regulatory mechanisms. Impor-
tantly, ZNF165 appears to be regulating the expression of a
number of proteins, which are implicated in tumour cell survival.
Further studies to determine the nature of ZNF165-mediated
gene regulation in vivo will be necessary to better understand how
ZNF165 promotes tumour progression. Importantly, our study of
ZNF165 reveals a critical contribution of an understudied
oncogene, WISP1, to TNBC, highlighting how elaboration of
CTA function can reveal cryptic aspects of the tumour cell
regulatory environment. The pro-tumorigenic features of TGFb
in late stage disease have made it a high value intervention target,
particularly in TNBC; however, TGFb is a pleiotropic cytokine
with important roles in normal physiology, thereby limiting the
efficacy of direct inhibition48. Our results suggest that ZNF165
may represent a mechanism to inhibit TGFb signalling in a
tumour cell-specific manner. This finding is also potentially
generalizable to additional signalling pathways as we find that the
CTAs, IGF2BP3 and SPANXA2 are sufficient to promote ligand-
stimulated activation of HIF and Wnt signalling, respectively.
In summary, our findings provide a comprehensive under-
standing of the phenotypes conferred by CTAs when aberrantly
Figure 5 | ZNF165 promotes TGFb pathway activation and drives expression of the WISP1 oncogene. (a) Immunoblots and Coomassie stain of TNBC
tissues. BA, benign-adjacent; N, normal; T, tumour. (b) ZNF165-V5 binding motifs. (c) Pathways enriched for WHIM12-ZNF165-V5-associated genes.
P value calculated using a binomial test. (d) WHIIM12 cells were transfected for 48 h with indicated siRNAs, stimulated with vehicle or 10 ng ml 1 of TGFb
for indicated times and mRNA expression quantitated by qPCR. Values are graphed relative to siCTRL at 0 min. Bars represent mean (n¼ 3)±s.e.m. P
values calculated by one-tailed, unpaired Student’s t-test for zero time points and two-tailed, paired Student’s t-test for all others. ****Pr0.0001,
***Pr0.0005, **Pr0.01, *Po0.05. (e) Relative mRNA expression of indicated genes was quantitated by qPCR in WHIM12-HcRed (CTRL) or WHIM12-
ZNF165-V5 cells. Bars represent mean (n¼ 3)±s.e.m. P value calculated from one-tailed Student’s t-test. *Pr0.05, **Pr0.01.
(f) Immunoblots of WHIM12 WCLs cells transfected with indicated siRNAs for 48 h. Data representative of three independent assays. (g) Left: WHIM12-
HcRED (CTRL) and WHIM12-ZNF165-V5 WCLs were immunoblotted as indicated. Right: 48 h after transient cDNA transfection, H1299 WCLs were
immunoblotted as indicated. Data representative of three independent assays. (h) Fraction of genes modulated following siZNF165 based on significant
analysis of microarrays analysis (criteria: false discovery rater10%, Student’s t-test Pr0.05). P values calculated by hypergeometric distribution analysis.
(i) TGFb-induced genes rank ordered based on fold change following siZNF165 and exposure to 10 ng ml 1 TGFb.(j) Left: WCLs from SUM159s transfected
with indicated siRNAs for 48 h were immunoblotted with indicated antibodies. Data representative of two independent assays. Right: mRNA was collected
in parallel and WISP1 expression quantitated by qPCR. Bars represent mean (n¼ 3)±range. (k) Left: RNA was isolated from WHIM12 cells stably
expressing ZNF165-V5 or HcRED (CTRL) and relative WISP1 mRNA was quantitated by qPCR. Bars represent mean (n¼ 2)±range. Right: WCLs were
immunoblotted with indicated antibodies. Data representative of three independent assays. (l) Viability assay following siWISP1. Values are graphed
relative to siCTRL. Bars represent mean (n¼ 3)±s.d.
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expressed in the tumorigenic regulatory environment. The
implications of these findings are twofold. First, the ectopic
expression of CTAs in a somatic cell can impart a neomorphic
function that may confer a selective advantage during tumor-
igenesis. Thus, annotation of CTA function reveals new aspects of
tumour biology not previously appreciated, which could answer
long-standing questions as to how tumour cells acquire specific
features (for example, suppressing death signalling, activating
epithelial-to-mesenchymal transition). Second, CTAs have long
been considered ideal targets for anti-cancer vaccines or adoptive
T-cell transfer. However, no objective criteria has been estab-
lished for selecting CTAs to therapeutically target. We propose
that CTAs with tumorigenic functions are the best candidates as
they are most likely expressed in the majority of tumour cells and
loss of expression would be detrimental to cancer cell survival.
Methods
Cell lines. Cell lines were obtained from American Tissue Type Collection
(ATCC) or John Minna (UT-Southwestern (UTSW)) except for: SK-MEL-2
(the National Cancer Institute); SK-MEL-37 and SK-OV-6 (Lloyd Old, Ludwig
Institute); SUM159, SUM229 and SUM149 (Asterand); HuMEC (Charles Perou,
the University of North Carolina at Chapel Hill, (UNC)); HME50-hTERT,
Fibroblasts (BJ) (Jerry Shay, UTSW); WHIM12 (Matthew Ellis, Baylor College
of Medicine); ES-2 (Rolf Brekken, UTSW); PEO1 and U2OS (Michael White,
UTSW); HEK293GP, HCC1806, Hs578t, MDA-MB-468 and MDA-MB-231 (Grey
Pearson, UTSW); RCC4 (William Kim, UNC); HCT116 (Cyrus Vaziri, UNC), and
HCT116-BAX /BAK / DKO (Bert Vogelstein, Johns Hopkins University).
All cell lines were cultured in provider’s recommended medium. Because SK-OV-6
is on the ICLAC list of misidentified cell lines, short tandem repeat profiling was
used to validate the line used in this study49. SK-OV-6 was used because it has
previously been demonstrated to express a number of CTAs1. Cells were evaluated
for mycoplasma contamination by DAPI stain for extra-nuclear DNA.
Antibodies and reagents. Antibodies used for immunoblotting were as follows:
Santa Cruz Biotechnology: GAPDH (sc-51907; 1:1,000), HA (sc-805; 1:500 and sc-
7392; 1:500), TOM20 (sc-11415; 1:500), BIK (sc-10770; 1:500 and sc-1710; 1:250),
c-Myc (sc-40; 1:1,000 and sc-789; 1:500), ERK1/2 (sc-93; 1:1,000), Ubiquitin
(sc-8017; 1:250), and FATE1 (sc-101220; 1:1,000); Sigma: FATE1 (HPA034604;
1:2,000) and RNF183 (SAB2106627; 1:1,000); Cell Signaling Technology: Cleaved
Caspase-3 (9661; 1:500), PARP1 (9532; 1:1,000), Bcl-xL (2764; 1:5,000) and
Phospho-SMAD2 (pSMAD2/3) (Ser465/467)/SMAD3 (Ser423/425) (8828;
1:1,000); Abcam: WISP1 (ab10737; 1:1,000), FATE1 (ab111486; 1:1,000) and
SMURF2 (ab53316; 1:1,000); ZNF165 (H00007718; 1:1,000; Novus Biologicals);
SMAD2/3 (07–408; 1:1,000; Millipore); V5 (R960; 1:1,000; Life Technologies).
Antibodies for immunofluorescence were as follows: c-Myc (sc-40; 1:100; Santa
Cruz Biotechnology), TOM20 (sc-11415; 1:500; Santa Cruz Biotechnology),
GM130 (ab31561; 1:100; Abcam), cytochrome c (556432; 1:200; BD Biosciences),
HA (MMS-101R; 1:100; Covance), Catalase (219010; 1:1,000; Calbiochem), V5
(R960; 1:300), Calnexin (ADI-SPA-860; 1:100; Enzo), COX IV (4850; 1:125; Cell
Signaling Technology), and b-tubulin (T5293; 1:100; Sigma).
Chemicals and reagents were purchased from the following manufacturers:
DMOG (Caymen Chemical); Wnt-3a (R&D Systems); tumour necrosis factor-a
(TNFa) (Promega); transforming growth factor-b (TGFb) (Cell Signaling); pan-
caspase inhibitor, (3S)-5-(2,6-difluorophenoxy)-3-[[(2S)-3-methyl-2-(quinoline-2-
carbonylamino)butanoyl]amino]-4-oxopentanoic acid (Q-VD-OPh) (Sigma).
siRNAs were obtained from GE Healthcare (siGENOME siRNA) or Sigma









































































































































































































































Figure 6 | ZNF165 supports TNBC tumour cell viability. (a) Viability
assays in indicated cells lines following siZNF165. Values represent viability
relative to siCTRL. Bars represent mean (n¼ 3)±s.d. (b) SUM159 and
WHIM12 cells were transfected with indicated siRNAs for 72 h and 48 h,
respectively, and WCL’s were immunoblotted as indicated. Data
representative of two independent assays. (c) Colony formation assays
performed in TNBC cell lines 48 h after transfection with siZNF165. Data
representative of at least two independent assays. Cell lines are indicated
across the top. (d) Left: RNA from WHIM12 cells expressing shCTRL or
shZNF165 was isolated and qPCR was used to quantitate relative ZNF165
mRNA. Bars are mean (n¼ 2)±range. Middle: growth curves of cells from
left panel injected s.c. and measured at indicated time points. Points
represent average volume of shCTRL (n¼ 11) or shZNF165 (n¼9)±s.e.m.,
P value calculated with unpaired, two-tailed Student’s t-test. ***Pr0.005.
Right: At the study endpoint (middle panel), tumours were excised and
weighed. Bars represent mean of tumour weights±s.e.m., P value
calculated with unpaired, two-tailed Student’s t-test. **Pr0.01. (e) Left:
Tumours from d, (middle panel) were stained for Ki-67. Bars represent
mean of total fluorescence across three randomly chosen fields for each
tumour±s.e.m. P value calculated with unpaired, two-tailed, Student’s
t-test. *Pr0.05. Right: Representative images from Ki-67 (green) stained
sections. Scale bars, 50mm.
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(GE Healthcare) or targeted genes DLNB14, FNDC3B or APOL6. CellTiter-Glo
(CTG), Apo-ONE Homogenous Caspase-3/7 (APO), ONE-Glo Luciferase Assay
System and Dual Glo Luciferase Assay System were purchased from Promega.
Lipofectamine RNAiMAX and the Click-iT EdU (5-ethynyl-20-deoxyuridine) Alexa
Fluor 488 Imaging kit were purchased from Thermo Fisher Technologies.
DharmaFECT reagents and DharmaFECT Duo were purchased from GE
Healthcare Life Sciences. TRIzol, Opti-MEM and Hoechst 3342, trihydrochloride,
trihydrate and MitoTracker Red CMXRos (C32H32Cl2N2O) were obtained from
Thermo Fisher Scientific.
Expression plasmids and mutagenesis. Unless otherwise specified full-length
complementary DNAs (cDNAs) were obtained from the CCSB-Broad lentiviral
open reading frame (ORF) collection (housed at UNC). Human ARMC3,
CTAGE1, CXORF48, DDX53, DPPA2, FAM46D, GAGE1, IGF2BP3, IGSF11,
IL13RA2, LDHC, MAGEA4, MAGEA5, MORC1, PAGE4, PIWIL2, PRAME,
SPANXC, XAGE2 and ZNF165 were obtained in pDONR223 and cloned into
pLX302 using the GatewayCloning system (Thermo Fisher Scientific). SPANXA2
and XAGE1B cDNAs were obtained in pLX304 (Thermo Fisher Scientific).
pCMV6-myc-ZNF165 was obtained from Origene (RC205600). Full-length FATE1
cDNA in pRK5 (a gift from Michael White, UTSW) was subcloned into pCMV-
myc (Clontech) and pcDNA3 (Thermo Fisher Scientific) between SalI and NotI,
and EcoRI and NotI, respectively. Myc-FATE1 cDNA was from pCMV-myc-FATE
was subcloned into pLPCX (Clontech) between BglII and NotI. Full-length
RNF183 cDNA was obtained in pLX304 and cloned into pCMV-HA (Clontech)
between SalI and NotI. Full-length BIK cDNA was obtained from pEGFP-BIK
(Addgene plasmid #10952). HA-RNF183-C13A/C59A and BIK-L61G, which has
limited toxicity as compared with wild type20, were generated using site-directed
mutagenesis. Bcl-xL cDNA (a gift from Mohanish Deshmukh, UNC) was cloned
into pCMV-myc between SalI and NotI and then myc-Bcl-xL cDNA was subcloned
into pLPCX between BglII and NotI. WISP1 ( 1 kb) promoter luciferase construct
was in pLightSwitch (Switchgear Genomics). eGFP cDNA (a gift from Michael
White, UTSW) was subcloned into pLPCX between BglII and NotI. Viral
packaging plasmids, pCMV-dr8.91 and pCMV-VSV-G, were a gift from William
Hahn (Harvard). For reporter assays using stable expression, the following
expression plasmids were used: TGFb: pSBE; WNT: pBAR (both gifts from Ben
Major, the University of North Carolina at Chapel Hill)50; and NF-kB:
pGreenFire1-NF-kB (SBI System Biosciences). For transient assays the following
reporters were used: TGFb: pTL-Luc.SMAD (LR0072, Affymetrix); Wnt: M50
Super 8X TOPflash in the pTA-Luc backbone (Addgene plasmid #12456); HIF:
pGL3-EPO-HRE3-SV40-LUC51 (a gift from David Siderovski, West Virginia
University) and pRL-CMV (a gift from Deborah Chapman, the University of
Pittsburgh). For ZNF165 shRNA, ZNF165-TRIPz-TetO-shRNA clones
V3THS_366604 and V3THS_366599 and TRIPZ-Non-Silencing Control
(RHS4743) were purchased from GE Healthcare Life Sciences.
CTA expression analysis and testbed assembly. For CTA expression analysis, a
multiplexed nCounter Gene Expression Codeset (NanoString Technologies) was
designed. CTA families with highly similar sequences, including GAGE, SPANX,
POTE, CTA45, CTA47, TSPY, MAGEA3&6 and XAGE were assessed by a single
expression probe. About 250 ng of mRNA from each cell line was used. Based on
NanoString expression values in 19 cell lines, an 11-cell line test bed was identified,
which exhibited maximum representation of target CTAs. NanoString probes
returning ambiguous expression values (defined as o1,000 counts in all settings)
were further evaluated by qPCR Taqman Real-Time PCR Assays (see below for
methods). Genes with Ct values o35 were considered expressed.
Whole genome expression analysis. Triplicate microarray analysis of SUM159
and WHIM12 cells depleted of ZNF165 for 60 h and 48 h, respectively, was
performed at the Functional Genomics Core (UNC) on Human GeneChip 1.0 ST
Arrays version 1.1 (Affymetrix). Microarray analysis was performed on 250 ng of
RNA isolated and terminally labelled with the Ambion WT Expression Kit
(Thermo Fisher Scientific). Raw data were normalized using robust multi-array
average and significant analysis of microarrays analysis identified significantly
modulated genes. Data sets were deposited at the NCBI Gene Expression Omnibus,
accession number GSE63986.
siRNA screen and data processing. Transfection conditions for each cell
line were optimized using the CTG assay and the formula: Transfection
Efficiency¼ 1 (LuminescencesiUBB/LuminescencesiCTRL). A custom siGenome
SMART pool siRNA library (Dharmacon/GE Healthcare Life Sciences) was pur-
chased in 96-well plate format and resuspended as described9. siRNAs were diluted
to 250 nM in serum-free medium and 30 ml of this solution (8.3 pmol of siRNA)
was mixed in well with appropriate transfection reagents in 9.8 ml Opti-MEM and
incubated for 20 min. Then, 60 or 80 ml of cells in growth medium were added for
cell biological and signalling assays, respectively. Cell biological screens were
performed 96 h post plating using 20 ml CTG (measuring cellular ATP; viability),
90ml APO (caspase-3/7 activity; survival) or the Click-iT EdU Alexa Fluor 488
Imaging Kit (DNA synthesis; proliferation) assay systems according to
manufacturer’s protocols. CTG and APO assays were read with a Pherastar Plus
or Pherastar FS (BMG Labtech) plate reader and EdU incorporation imaged using
a Cellomics ArrayScan HCS Reader (Thermo Fisher Scientific). Incorporation was
calculated as indicated by EdU-positive nuclei/total nuclei via staining with
Hoechst 3342, trihydrochloride and trihydrate. For the HIF screen, 100 ng of
pGL3-EPO-HRE3-SV40-LUC, 2 ng of pRL and 8.3 pmol of siRNA were reversed
transfected with DharmFECT Duo. Cells were treated with 1 mM DMOG or
vehicle 32 h after transfection. After an additional 16 h, firefly and renilla luciferase
levels were quantitated with Dual Glo Luciferase Assay System modified to use
20 ml of both the Luciferase and Stop and Glo reagents per well. For other signalling
assays, 44 h post transfection, cells were exposed to vehicle or ligand for 16 h and
luciferase activity measured using the ONE-Glo Luciferase Assay System modified
to use 20 ml of OneGlo reagent per well. All luminescence assays were measured on
a PHERAstar Plus. Raw values for each cell biological screen were normalized to a
non-targeting control (siGENOME Non-Targeting siRNA Pool#2 (GE Healthcare
Life Sciences)). Raw data were first normalized to CTG values taken in parallel to
correct for viability defects (with the exception of the HIF screen, which used
renilla luminescence values) and then z-scores were calculated. siRNA pools with
z-scores 42 in the apoptosis screen or o 2 in the viability and proliferation
screens were considered outliers. Only siRNA pools that exhibited statistically
significant change (Pr0.05 by unpaired Student’s t-test) were considered. For the
HIF, NF-kB, Wnt and TGFb reporter screens, siRNA pools that reduced reporter
activity by either 460% in a single cell line or 430% in more than two cell lines
were considered positives. For the NF-kB, Wnt and TGFb signalling screens, both
basal- and ligand-induced values were considered.
Transfections. For siRNA transfection, cells were trypsinized and plated into
medium containing 50–100 nM siRNA complexed with RNAiMAX in Opti-MEM
and incubated as indicated in the figure legends. For cDNA transfections, HeLa,
H1155 and H1299 cells were transfected using Lipofectamine 2000 (Thermo Fisher
Scientific) and HEK293T cells were transfected using FuGENE 6 or the calcium
phosphate method52. All manufacturers’ protocols were followed.
Generation of stable cell lines. Cell lines stably expressing luciferase reporters
and WHIM12-HcRed and WHIM12-ZNF165-V5 cell lines were created via len-
tiviral-mediated gene transduction through co-transfection of HEK293T cells with
viral expression and packing plasmids (pCMV-VSV-G and pCMV-dr8.91). For
FATE1 studies, stable lines were created via retroviral-mediated gene transduction
through co-transfection of HEK293GP cells with pLPCX expression plasmids and
pCMV-VSV-G. Virus conditioned media was used to infect target cells in the
presence of polybrene and stable populations were selected using appropriate
antibiotics.
Luciferase assays. Indicated luciferase reporters (100 ng), Renilla reporter
(pRL-CMV, 2 ng) and 100 ng indicated cDNAs were transfected into HEK293T
using Fugene 6. Forty-eight hours later, luciferase activity was measured using the
Dual Glo Luciferase Assay System. For WISP1 promoter luciferase assay, 100 ng of
the pLightSwitch-WISP1( 1 kb) promoter was used and luciferase activity was
quantitated with Renilla Luciferase Assay System (Promega). Luciferase values were
normalized to CTG in parallel samples.
Colony formation assay. At indicated incubation times following siRNA trans-
fection, cells were replated at limiting dilution, fed every other day and stained with
Geimsa (Sigma).
Gene expression. RNA was isolated using TRIzol or an RNA isolation kit (Sigma)
and reverse transcribed using the High-Capacity cDNA Reverse Transfection Kit
(Thermo Fisher Scientific) according to manufacturer’s instructions. An Applied
Biosystems Real-Time PCR system and either Solaris (Dharmacon), SYBR Green
or TaqMan Real-Time PCR (Thermo Fisher Scientific) gene expression assays were
used. Gene expression assays were multiplexed with RPL27, GAPDH or actin as
control assays. Relative expression values were calculated using the comparative
2DDCT method53. Primer sequences or catalogue numbers can be found in
Supplementary Data 7.
Immunoblotting. Whole cell lysates were prepared in 2 Laemmli sample buffer
and resolved using SDS–PAGE. Gels were transferred to Immobilon PVDF
(Millipore) or nitrocellulose (Bio-Rad Laboratories) membranes, blocked in either
tris-buffered saline containing 0.1% Tween-20 (TBST) and 5% non-fat dry milk or
5% bovine serum albumin (BSA), or Odyssey (LI-COR Biosciences) blocking buffer
followed by incubation with indicated primary antibodies for 1 h or overnight.
After washes in TBST, appropriate horseradish peroxidase-coupled secondary
antibodies (Jackson Immunoresearch) or IRDye antibodies (LI-COR Bioscience)
were used for chemiluminescence or fluorescence detection (Odyssey), respectively.
Whole immunoblots are provided in Supplementary Figs 5–10.
Immunofluorescence. Cells plated on glass coverslips were fixed with 3.7% for-
maldehyde and then permeabilized with 0.5% Triton X-100 for 10 min. For
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9840
12 NATURE COMMUNICATIONS | 6:8840 | DOI: 10.1038/ncomms9840 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
calnexin staining, cells were permeabilized with ice-cold methanol for 10 min. Cells
were blocked and washed in 1% BSA, 0.1% Tween-20 in 1 phosphate buffered
saline (PBS) (PBTA). Cells were incubated with primary antibodies for 1 h followed
by three washes in PBTA. Coverslips were then incubated with Alexa Fluor-
conjugated secondary antibodies (Thermo Fisher Scientific) for 30 min followed by
three washes in PBTA and a wash in H2O. MitoTracker was added for 30 min prior
to fixation. Prolong Gold Antifade reagent with DAPI (Thermo Fisher Scientific)
was used to mount slips on glass slides and images were acquired on either a Leica
DM55000 B upright microscope, a Leica TCS SP5 confocal microscope, a Zeiss
Axioimager upright microscope or a Zeiss LSM510 confocal microscope.
Viability assays. Cells were reverse transfected with RNAiMAX in Opti-MEM
with 50–100 nM siRNA in 96-well format. In TNBC assays, cells were fed at 48 h.
About 96 h post transfection (unless otherwise indicated), CTG was used to
quantitate total ATP using a Pherastar Plus plate reader.
Immunoprecipitation. Unless otherwise indicated, cells where lysed on ice for
30 min in non-denaturing lysis buffer (NDLB): 50 mM HEPES pH 7.4, 1.0% Triton
X-100, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM NaVO4, 25 mM b-Gly-
cerophosphate, 1 mM ethylenediaminetetraacetic Acid (EDTA), 1 mM ethylene
glycol tetraacetic acid (EGTA), 1 mg ml 1 pepstatin, 2 mg ml 1 leupeptin,
2 mg ml 1 aprotinin and 50mM bestatin. Lysates were clarified at 12,000g for
10 min. Then, 10% of each clarified lysate was set aside as an input loading control
and the remainder was immunoprecipitated for 4 h at 4 C with antibodies coupled
to Protein A/G beads. Unless otherwise indicated, beads were washed two times in
high salt (350 mM NaCl) NDLB, once in NDLB and then resuspended and boiled
in 2 Laemmli sample buffer.
Autoubiquitination assays. For in vitro autoubiquitination assays, HEK293T
were transfected with pCMV-HA-RNF183 or pCMV-HA-RNF183-CC/AA.
Twenty-four hours after transfection, cells were lysed on ice in NDLB, pH¼ 8.0,
clarified at 12,000g for 10 min and then immunoprecipitated for 4 h with anti-HA
antibody (Covance) and Protein A/G beads (Life Technologies). Beads were then
washed three times in NDLB with 350 mM NaCl and two times in ligase buffer:
50 mM Tris pH 7.5, 150 mM KCl, 1 mM MgCl2. After the final wash, beads were
resuspended in ligase buffer containing 100 nM recombinant E1 (Enzo Life
Sciences), 1 mM recombinant UbcH5b (Enzo Life Sciences), 5 mM ubiquitin from
bovine erythrocytes (Sigma), plus or minus 5 mM Mg2þ ATP and incubated for
1.5 h at 37 C.
ChIP and ChIP-Seq. WHIM12-ZNF165-V5 cells were grown to 75% confluency
and cross-linked with 1% formaldehyde for 10 min at 25 C. Crosslinking was
quenched with 125 mM glycine. Nuclei were isolated by dounce homogenization in
hypotonic buffer (20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 10% glycerol,
1 mg ml 1 pepstatin, 2 mg ml 1 leupeptin, 2 mg ml 1 aprotinin and 50mM besta-
tin) followed by centrifugation at 600g for 5 min and then lysed in RIPA buffer
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1.0 mM EDTA, 1.0% Sodium Deox-
ycholate, 0.1% SDS, 1.0% NP-40, 0.2 mM NaVO4, 1 mg ml 1 pepstatin, 2 mg ml 1
leupeptin, 2 mg ml 1 aprotinin and 50mM bestatin). DNA was sheared to a range
of 300–500-bp fragments. Chromatin was immunoprecipitated using 2 mg of ChIP-
Grade anti-V5 (Abcam ab9116) overnight at 4 C followed by a 2-h incubation
with Protein A/G beads. ChIPed DNA was recovered by reverse crosslinking with
an overnight incubation at 65 C. Excess RNA and protein were removed,
respectively, with 100 mg RNAse and 10mg Proteinase K, and the remaining DNA
was purified using the Zymogen Zymo-Spin ChIP-Grade DNA Clean-Up Kit.
For sequencing of chromatin immunoprecipited DNA, 5 ng of immuno-
precipitated DNA underwent library preparation using the KAPA HTP Library
Preparation Kit. Sequencing was performed on the Illumina HiSeq 2500 using
50SR V3 reagents. Following sequencing, HOMER findPEAKS module was used to
identify significantly enriched peaks using a false discovery rate cutoff r0.001, a
cumulative Poisson P value and required fourfold or more enrichment of the ratio
of normalized sequence reads in the experimental sample to the normalized
sequences reads in the input sample. GREAT was used to assign peak regions to
genes and evaluate pathway enrichment54,55. HOMER package v4.2
findmotifsGenome.pl module with settings:  size150  S 10-bits56 was used for
de novo motif analysis. Motif analysis was restricted to 150 bp surrounding peak
summit. ChIP-Seq data sets were deposited at the NCBI Gene Expression
Omnibus, accession number GSE63986.
ChIP–qPCR analysis. ChIP–qPCR analysis was conducted using custom SYBR
Green assays designed to ChIP-Seq peaks (See Supplementary Data 7). The ACRBP
ORF lacked enrichment in the WHIM12-ZNF165-V5 ChIP-Seq and was used as a
negative control for ZNF165-V5 binding. ZNF165-V5 occupancy was evaluated
with immunoprecipitation efficiency using per cent of total input DNA of
WHIM12-CTRL and WHIM12-ZNF165-V5 cells.
Xenograft injections. WHIM12 cells (650,000) stably expressing ZNF165-TRIPz-
TetO-shRNA or a non-targeting control hairpin in 200 ml PBS were injected in the
right flank of 4–6-week-old female NOD.cg-PRKDCSCIDIl2rgtm1Wjl/SzJ (NSG)
mice. Twenty-four hours prior to injection, cells were exposed to 1 mg ml 1
doxycycline and mice were administered water containing 2 mg ml 1 doxycycline
and 1% sucrose ad libitum. Tumours were measured twice weekly using a digital
caliper and volume (V) was calculated using the formula: V¼ (Longest side)(-
perpendicular to longest side)2/(p/6). Tumours were surgically removed, weighed,
formalin fixed for 48 h, sectioned (5 mm) and immuonostained with
Ki-67. Ki-67 fluorescence (FluorescenceTotal FluorescenceBackground) was calcu-
lated using the ImageJ integrated density function. All studies were conducted in
accordance with a UTSW Institutional Animal Care and Use Committee (IACUC)
approved protocol.
Human breast tissue. All human breast tissue was obtained from the UNC
Lineberger Tissue Procurement center in compliance with guidelines of the UNC
Internal Review Board committee. All human tissues were obtained with informed
consent. Samples were homogenized in lysis buffer (1% Triton X-100, 50 mM
HEPES pH 7.6, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 25 mM b-glycer-
olphosphate, 10% Glycerol, 1 mM EGTA, 1 mM NaVO4, 1 mg ml 1 pepstatin,
2 mg ml 1 leupeptin, 2 mg ml 1 aprotinin and 50 mM bestatin). Samples were
sonicated and the soluble fraction recovered by centrifugation. Protein con-
centrations were quantitated using Bio-Rad Protein Assay Dye Reagent. Samples
were diluted to 1 mg ml 1 in 4 Laemmli sample buffer and immunoblotted as
described above. Coomassie stain (Genlantis) was incubated with SDS–PAGE gels
for 30 min followed by destain for 4 h.
Oncomine analysis. For Oncomine BIK mRNA tumour/normal analysis, the
following studies were used: GSE16515, GSE2514 and TCGA Research Network
(http://cancergenome.nih.gov/)57–60. For Oncomine ZNF165 mRNA tumour/
normal analysis, the following studies were used: GSE4336, GSE6764, GSE12470
and GSE7410 (refs 61–64).
Survival analysis. The overall survival and clinicopathological data sets were
GSE8894, Lung Adenocarcinoma and Colorectal TCGA (downloaded from cBio-
Portal)60,65, Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC) and GSE42127, the latter was supplemented to 209 cases66. Samples
were placed into groups based on a median cutoff, with the exception of the
colorectal patients in Fig. 3j, where a z-score cutoff of expression 41.5 was used
and METABRIC patients where the gene expression low and high cutoff point was
determined by the mclust R version 4 from the R package67. The distributions of
time-to-event outcomes were estimated using the method of Kaplan and Meier.
P values and HRs were calculated using a Cox regression model.
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